November 20, 2026
Source: drugdu
36

On November 19, Lianhuan Pharmaceutical announced that China’s National Medical Products Administration had approved its marketing application for bilastine API. Bilastine is a long-acting, nonsedating antihistamine that selectively antagonizes peripheral H1 receptors. It has no affinity for muscarinic receptors and low affinity for other receptors.
Source: http://finance.eastmoney.com/a/202611193935255859.html
By editoryour submission has already been received.
OK
Please enter a valid Email address!
Submit
The most relevant industry news & insight will be sent to you every two weeks.